Detalles de la búsqueda
1.
Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit.
Cancer Sci
; 115(3): 752-762, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38254257
2.
Butyricimonas is a key gut microbiome component for predicting postoperative recurrence of esophageal cancer.
Cancer Immunol Immunother
; 73(2): 23, 2024 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38280026
3.
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.
Cancer Immunol Immunother
; 70(2): 337-348, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32757055
4.
Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report.
World J Gastrointest Oncol
; 16(2): 557-562, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38425406
5.
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody.
Sci Rep
; 14(1): 11325, 2024 05 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38760458
6.
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
Anticancer Res
; 44(1): 23-29, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38159965
7.
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.
Front Oncol
; 13: 1231986, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496666
8.
Monocyte subsets associated with the efficacy of antiPD1 antibody monotherapy.
Oncol Lett
; 26(3): 381, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37559573
9.
Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor.
Front Immunol
; 14: 1164724, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207204
10.
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Front Immunol
; 14: 1260492, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37790929
11.
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
Medicine (Baltimore)
; 101(2): e28339, 2022 Jan 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35029177
12.
The Prognostic Impact of Eosinophils and the Eosinophil-to-Lymphocyte Ratio on Survival Outcomes in Stage II Resectable Pancreatic Cancer.
Pancreas
; 50(2): 167-175, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33565793
13.
Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure.
Cancer Chemother Pharmacol
; 88(3): 543-553, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117512
14.
Examination of endobronchial ultrasound-guided transbronchial needle aspiration using a puncture needle with a side trap.
Sci Rep
; 11(1): 9789, 2021 05 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33963234
15.
Increased Plasma Soluble PD-1 Concentration Correlates with Disease Progression in Patients with Cancer Treated with Anti-PD-1 Antibodies.
Biomedicines
; 9(12)2021 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34944745
16.
Rare Nivolumab-associated Super Hyper Progressive Disease in Patients With Advanced Gastric Cancer.
In Vivo
; 35(3): 1865-1875, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33910874
17.
High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer.
Int J Oncol
; 58(1): 57-69, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33367933
18.
A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
Medicine (Baltimore)
; 100(23): e25774, 2021 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34114983
19.
Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
Anticancer Res
; 41(10): 4985-4993, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593446
20.
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
Cancer Chemother Pharmacol
; 85(6): 1119-1128, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32458030